Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M19,901Revenue (TTM) $M10,300Net Margin (%)2.5Altman Z-Score0.9
Enterprise Value $M34,463EPS (TTM) $0.5Operating Margin %7.9Piotroski F-Score3
P/E(ttm)72.9Beneish M-Score-2.7Pre-tax Margin (%)1.1Higher ROA y-yN
Price/Book1.710-y EBITDA Growth Rate %13.1Quick Ratio0.6Cash flow > EarningsY
Price/Sales1.85-y EBITDA Growth Rate %7.5Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow11.4y-y EBITDA Growth Rate %-19.9ROA % (ttm)1.0Higher Current Ratio y-yN
Dividend Yield %--PEG9.6ROE % (ttm)2.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M535ROIC % (ttm)4.1Gross Margin Increase y-yN

Gurus Latest Trades with MYL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYLDavid Einhorn 2016-09-30 Add1.06%$38.12 - $49.92
($44.46)
$ 37.19-16%Add 29.42%6,400,000
MYLJohn Paulson 2016-09-30 Reduce-0.1%$38.12 - $49.92
($44.46)
$ 37.19-16%Reduce -0.98%21,811,661
MYLVanguard Health Care Fund 2016-09-30 Add0.1%$38.12 - $49.92
($44.46)
$ 37.19-16%Add 4.23%29,148,837
MYLJoel Greenblatt 2016-09-30 Buy 0.01%$38.12 - $49.92
($44.46)
$ 37.19-16%New holding21,460
MYLMario Gabelli 2016-09-30 Add$38.12 - $49.92
($44.46)
$ 37.19-16%Add 14.37%16,012
MYLDavid Einhorn 2016-06-30 Add1.63%$38.62 - $48.8
($44.27)
$ 37.19-16%Add 71.11%4,945,000
MYLJohn Paulson 2016-06-30 Reduce-0.46%$38.62 - $48.8
($44.27)
$ 37.19-16%Reduce -5.60%22,028,061
MYLJoel Greenblatt 2016-06-30 Sold Out -0.44%$38.62 - $48.8
($44.27)
$ 37.19-16%Sold Out0
MYLVanguard Health Care Fund 2016-06-30 Add0.12%$38.62 - $48.8
($44.27)
$ 37.19-16%Add 4.82%27,965,385
MYLMario Gabelli 2016-06-30 Reduce$38.62 - $48.8
($44.27)
$ 37.19-16%Reduce -17.65%14,000
MYLDavid Tepper 2016-03-31 Sold Out -0.92%$41.42 - $54.09
($48.28)
$ 37.19-23%Sold Out0
MYLJoel Greenblatt 2016-03-31 Add0.44%$41.42 - $54.09
($48.28)
$ 37.19-23%Add 9178.19%837,728
MYLVanguard Health Care Fund 2016-03-31 Add0.25%$41.42 - $54.09
($48.28)
$ 37.19-23%Add 10.00%26,679,385
MYLJohn Paulson 2016-03-31 Add0.19%$41.42 - $54.09
($48.28)
$ 37.19-23%Add 2.38%23,335,861
MYLKeeley Asset Management Corp 2016-03-31 Sold Out -0.09%$41.42 - $54.09
($48.28)
$ 37.19-23%Sold Out0
MYLMario Gabelli 2016-03-31 Reduce$41.42 - $54.09
($48.28)
$ 37.19-23%Reduce -35.73%17,000
MYLDavid Einhorn 2015-12-31 Buy 2.86%$39.16 - $55.28
($48.35)
$ 37.19-23%New holding2,890,000
MYLDavid Tepper 2015-12-31 Add0.41%$39.16 - $55.28
($48.35)
$ 37.19-23%Add 81.62%853,749
MYLJohn Paulson 2015-12-31 Add0.29%$39.16 - $55.28
($48.35)
$ 37.19-23%Add 4.02%22,794,061
MYLVanguard Health Care Fund 2015-12-31 Add0.11%$39.16 - $55.28
($48.35)
$ 37.19-23%Add 4.26%24,253,075
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BRESCH HEATHER MCEO 2016-08-09Sell100,200$50-25.62view
MAROON JOSEPH C MDDirector 2016-06-03Buy1,670$44.95-17.26view
MAROON JOSEPH C MDDirector 2016-05-25Buy2,370$42.47-12.43view
Cindrich Robert JDirector 2016-05-25Buy1,190$42.47-12.43view
HIGGINS MELINA EDirector 2016-05-12Buy19,900$38.68-3.85view
HIGGINS MELINA EDirector 2016-05-06Buy100$38.69-3.88view
HIGGINS MELINA EDirector 2016-04-28Buy35,000$42.92-13.35view
COURY ROBERT JExecutive Chairman 2016-04-05Sell217,755$45.96-19.08view
MAROON JOSEPH C MDDirector 2016-03-31Buy4,337$46.36-19.78view
PARRISH MARK WDirector 2016-03-17Buy1,705$44-15.48view

Press Releases about MYL :

Quarterly/Annual Reports about MYL:

News about MYL:

Articles On GuruFocus.com
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Weak Outlook on Mylan Nov 18 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Mylan Posts Loss Amid Investigation, Settlement Nov 10 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 
Allergan: Trading at a Low Earnings Multiple Nov 06 2016 
David Einhorn Converses on Range of Topics, Stocks With New York Times Editor Oct 20 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 

More From Other Websites
ETFs with exposure to Mylan NV : January 17, 2017 Jan 17 2017
CVS takes on Mylan’s EpiPen with much cheaper version of an alternative Jan 15 2017
Examining Volkswagen and Fiat Chrysler's Emissions Cheating Scandals Jan 13 2017
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks... Jan 13 2017
Mylan’s Recent Commercial and Product Developments Jan 13 2017
Mylan NV breached its 50 day moving average in a Bearish Manner : MYL-US : January 13, 2017 Jan 13 2017
Blog Coverage Expensive EpiPen Proves Costly for Mylan as Cigna Drops it from Coverage List; Opts... Jan 13 2017
Mylan’s Profit Margins: What Made Them Change? Jan 13 2017
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News Jan 13 2017
Business Watch Jan 13 2017
UPDATE 1-CVS slashes price of Impax's EpiPen rival Jan 12 2017
CVS slashes price of Impax's emergency allergy shot Jan 12 2017
Mylan Crushed by Trump, Cigna and CVS -- All In Two Days Jan 12 2017
[$$] Cigna Drops EpiPen Coverage for Generic Jan 12 2017
Pharma company executives debate drug pricing increases Jan 12 2017
CVS Debuts Cheap EpiPen Alternative Jan 12 2017
Mylan CEO Heather Bresch says caps on drug price increases won’t work Jan 12 2017
CVS Is the Latest to Rock Mylan's EpiPen Empire Jan 12 2017
Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales Jan 12 2017
CVS generic competitor to EpiPen, sold at a 6th the price Jan 12 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)